Phase II trial of anaxirone (1,2,4-triglycidylurazol, TGU) in patients with advanced ovarian carcinoma: an EORTC Gynecological Cancer Cooperative Group Study.

Sixteen patients with advanced ovarian carcinoma were treated with anaxirone (1,2,4-triglycidylurazol, TGU), 600 mg/m2 every 4 weeks. Anaxirone was the second or later line of therapy. All patients had evaluable tumors and evidence of failure of prior therapy. None of the patients responded. Two had stabilization of the disease for 4 months. In one patient WHO grade 4 leukopenia and grade 4 thrombocytopenia were observed after the second TGU cycle starting on day 41 and persisted until the patient died due to tumor progression (day 50). No patient experienced thrombophlebitis.
AuthorsM George, V Scotto, F Carnino, P Dodion, W W ten Bokkel Huinink, N Rotmensz, J B Vermorken
JournalEuropean journal of cancer & clinical oncology (Eur J Cancer Clin Oncol) Vol. 23 Issue 6 Pg. 867-9 (Jun 1987) ISSN: 0277-5379 [Print] ENGLAND
PMID3653204 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Triazoles
  • anaxirone
  • Adult
  • Aged
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Drug Evaluation
  • Female
  • Humans
  • Middle Aged
  • Ovarian Neoplasms (drug therapy)
  • Triazoles (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: